[go: up one dir, main page]

WO1997047766A1 - Identification precise et rapide de variantes de sequences d'adn par spectrometrie de masse en phase ionisee par electro-pulverisation - Google Patents

Identification precise et rapide de variantes de sequences d'adn par spectrometrie de masse en phase ionisee par electro-pulverisation Download PDF

Info

Publication number
WO1997047766A1
WO1997047766A1 PCT/US1997/008518 US9708518W WO9747766A1 WO 1997047766 A1 WO1997047766 A1 WO 1997047766A1 US 9708518 W US9708518 W US 9708518W WO 9747766 A1 WO9747766 A1 WO 9747766A1
Authority
WO
WIPO (PCT)
Prior art keywords
mass
amplified dna
mass spectrometry
electrospray ionization
desalting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/008518
Other languages
English (en)
Inventor
Chris E. Hopkins
Raymond F. Gesteland
Andy Peiffer
Dora Stauffer
Mark Leppert
Pamela F. Crain
James A. Mccloskey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Priority to EP97930985A priority Critical patent/EP0954611A1/fr
Priority to JP10501607A priority patent/JP2000512497A/ja
Publication of WO1997047766A1 publication Critical patent/WO1997047766A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism

Definitions

  • This invention relates to detection of differences between nucleic acids. More particularly, the invention relates to rapid and accurate detection of differences between selected nucleic acids by electrospray mass spectrometry.
  • Sequencing a sample in which the locus for a polymorphism is identical for both chromosomes (a homozygote) generally provides a clean signal of the base composition for the polymorphic locus.
  • the sequencing signal is complex.
  • base-substitution polymorphisms sequencing generates a multiple base signal for the polymorphic position.
  • base-deletion or base-insertion polymorphisms sequencing generates multiple base signals starting at the polymorphic locus and propagating throughout the rest of the sequence.
  • OLA oligonucleotide ligation assay
  • mismatch PCR mismatch PCR
  • engineered restriction enzyme site analysis were developed.
  • two primers are designed to anneal adjacently on a genomic, amplified template.
  • thermocycling in the presence of a thermostable ligase covalently links the primers if they anneal to the template without a gap between them and without a mismatch at the ends to be joined.
  • This technique, and other similar techniques is simple and about 5- times faster than sequencing, but it suffers from the drawback of requiring sequence-specific optimization to reduce false positives or false negatives.
  • SBH sequence-based hybridization
  • the size of the amplified DNA segment is to be limited only by functionality in detecting mass differences between the mass of the amplified DNA segment and the reference mass, the size of the amplified DNA segment is preferably no greater than about 55 base pairs, more preferably no greater than about 50 base pairs, and most preferably no greater than about 45 base pairs.
  • a method of detecting heterozygosity at a polymorphic site in the genome of an individual, wherein the polymorphic site comprises a site at which a base substitution or base deletion or insertion occurs in a mutant allele as compared to a wild type allele comprises the steps of:
  • a method of detecting a polymorphism at a polymorphic site comprising a base substitution or a base deletion or insertion comprises the steps of:
  • FIG. 1 shows a mass-to-charge (m/z) spectrum of a 53-base oligonucleotide (SEQ ID N0:1), wherein the values in brackets denote measured m/z values and the superscripts denote calculated charges.
  • FIG. 2 shows a molecular weight transform spectrum obtained from the mass-to-charge spectrum of FIG. 1.
  • FIG. 3 shows an m/z spectrum of PCR-amplified DNA.
  • FIG. 4 shows a molecular weight transform spectrum obtained from the m/z spectrum of FIG. 3.
  • FIG. 5 shows (A) a molecular weight transform spectrum obtained from PCR-amplified DNA wherein the template genomic DNA displayed homozygosity at the polymorphic site, and (B) a molecular weight transform spectrum obtained from PCR-amplified DNA wherein the template genomic DNA displayed heterozygosity at the polymorphic site.
  • FIG. 6 shows molecular weight transform spectra of pairwise mixtures of synthetic 53-residue oligonucleotides, wherein the paired oligonucleotides differ only by a single base, as follows: (A) C and A;
  • FIG. 7 shows molecular weight transform spectra showing detection of alleles for a C to T base substitution polymorphism according to the present invention: (A) heterozygous mother,- (B) heterozygous father; (C) homozygous daughter 1; (D) homozygous daughter 2; (E) theoretical molecular weights of amplified DNA strands from allele 1; (F) theoretical molecular weights of amplified DNA strands from allele
  • FIG. 8 shows molecular weight transform spectra showing detection of alleles for a two-base deletion polymorphism according to the present invention: (A) heterozygous mother; (B) father homozygous for allele
  • an amplified segment includes reference to two or more of such amplified segments
  • a polymerase includes reference to a mixture of two or more of such polymerases
  • reference to “a primer” includes reference to two or more of such primers.
  • genomic DNA or similar terms includes reference to transcription products of such genomic DNA. It is well known in the art that RNA can be readily copied as cDNA, which can be amplified by PCR. Thus, amplification of genomic DNA and amplification of cDNA obtained from RNA are considered equivalent.
  • Mass spectrometry provides a new method of DNA sequence analysis because differences in sequence composition can be measured from mass differences.
  • Mass spectrometry is capable of very rapid sample analysis. For example, mass analysis of sequencing reaction products by electrospray ionization Fourier transform ion cyclotron resonance (ESI-FTICR) achieves mass analysis detection of all the reaction products with a 20-second sampling of the ion beam. Even though most mass spectrometric detectors are capable of determining the mass of components in a sample in less than a second, the rate for sample analysis is limited to about 15 minutes per sample due to other factors, such as signal averaging and sample handling. Matrix-assisted laser desorption ionization time-of- flight mass spectrometry (MALDI-TOF) has been demonstrated as a viable technique for analysis of polymorphisms. L.Y. Ch'ang et al., Detection of delta
  • Mass spectrometric analysis has two stages, ionization and ion analysis.
  • the ionization process employs either electrospray ionization (ESI) or Matrix-assisted laser desorption ionization (MALDI) .
  • the typical analysis hardware for either of these two ionizers can include ion trap (IT) , time-of-flight (TOF) , quadrupole, or Fourier transform ion cyclotron resonance (FTICR) analyzers.
  • ESI is typically interfaced with a quadrupole analyzer
  • MALDI is generally coupled with a TOF analyzer.
  • the accuracy of mass analysis using these methods is approximately as shown in Table l.
  • Table 2 shows the absolute value of the mass differences for these six types of substitutions in double-stranded DNA.
  • Table 3 shows the absolute value of the mass differences for these six types of substitutions in single-stranded DNA.
  • the mass differences for these six types of base substitutions are only 0 or 1 dalton.
  • the mass differences range from 9-40 daltons. Therefore, for base-substitution DNA polymorphisms to be analyzed by their mass differences, the samples must be denatured to single strands.
  • the separate mass analysis of each of the two strands of double-stranded DNA provides two independent measurements of allelic composition. ESI-quadrupole analysis is ideally suited for analysis of base substitutions because it is inherently single-strand analysis.
  • An ESI-MS analyzer is capable of measuring very large ions because, as for all mass analyzers, the property measured is mass to charge ratio (m/z) , and not mass directly.
  • Analysis of nucleic acids is generally performed in negative ion mode. As the nucleic acid enters the gas phase, the phosphate backbone oxyanions, all of which are charged in solution, are partially neutralized by proton adduction. The amount of neutralization of oxyanion charge varies between the molecules and thus results in a population of molecules with varying charge states by integral increments.
  • mass analysis of a compound by mass spectrometry generates a series of m/z peaks, where the charge state of the peaks increases as the value of measured m/z decreases.
  • ESI-MS analysis of a synthetic oligonucleotide containing 53 nucleotide residues generates a series of m/z peaks (FIG. 1) .
  • the value inside the brackets is the measured m/z, and the superscript value is the calculated charge.
  • M analyte mass
  • m/z charge-to-mass ratio
  • Z the value of the charge.
  • This formula is used to calculate the charge from the measured value of two m/z peaks and their integral relationship of charge.
  • the mass of the compound can be calculated from each m/z peak, and thus provide multiple measurements of molecular weight, as shown in Table 4.
  • the average of the masses calculated from each m/z peak determines mass accuracy to within 0.01% mass error.
  • a computer can automatically transform an m/z spectrum into a molecular weight spectrum according to the Fenn method, J.B. Fenn et al. , Electrospray Ionization for Mass Spectrometry of Large Biomolecules, 246 Science 64-70 (1989) , hereby incorporated by reference, and thus render a molecular weight peak for each related m/z series, as shown in FIG. 2.
  • salt e.g. Na' or K +
  • This salt adduction generates additional peaks in the ESI-MS spectrum.
  • the two peaks to the right of the main peak are salt adducts of Na + and 2 Na 4 .
  • salt adduction peaks become the primary species observed. This is undesirable for at least two reasons. First, the intensity of the signal is decreased by distributing the analyte mass over multiple peaks with varying amounts of salt adduction. Second, the mass spectrum of a complex mixture is confused by a much higher degree of m/z peak overlap.
  • PCR primers are designed to flank a polymorphic locus such that the nucleotide base pairs involved in the polymorphism are not defined by the primers.
  • the distance between the primers is about 1-5 nucleotides.
  • amplification In heterozygous individuals, where the sequence composition at the locus is different for each chromosome (two different alleles) , amplification generates two slightly different dsDNA products. Using ESI-quadrupole mass spectrometry, the molecule weight of each of the strands of a dsDNA PCR product can be measured. Each strand can be assigned to an allele type by comparison of the observed molecular weight to the expected weight of the allele types.
  • ESI-MS provides several advantages over methods known in the art.
  • the ESI-MS technique is highly specific.
  • the small size of amplified products enables observation of very narrow windows into the genome. Only the region of DNA between the DNA primers, i.e. the window, represents the genomic DNA.
  • the primers define the polymerization of their opposite strand base pairs.
  • the ESI-MS technique does not require empirical optimization of analysis conditions to elucidate polymorphy. Once the PCR amplification has been optimized for specificity and yield, the preparation of samples for mass analysis is the same for any amplified product. As a result, successful ESI-MS analysis appears to be dependent primarily on sample cleanup and to be independent of nucleotide composition. Electrophoretic techniques such as SSCP, however, require extensive exploration of running conditions to detect specific polymorphisms. Mismatch PCR and polymorphism selective restriction site engineering both are site-specific, thus must be re-optimized for each locus analyzed.
  • Enhanced resolution of a T-to-A base-substitution polymorphism can be achieved on a quadrupole detector by substituting deoxyuridine for deoxythymidine in the PCR reaction protocol. This modification results in a 23-dalton separation between the alleles, thus enabling a quadrupole detector to readily distinguish the alleles of all types of base substitution polymorphisms in a 53-nucleotide substrate.
  • ESI-MS is complementary to current technology by enabling confirmation of putative polymorphic loci and then rapid screening of sample sets.
  • the ESI-MS technique improves reliability of diagnosis because it directly measures the mass of the alleles involved in a polymorphism, not their relative mobilities.
  • ESI-MS analysis appears well suited for detecting base- substitution polymorphisms or base deletion/insertion polymorphisms, which are difficult to detect by current methods.
  • Many disease genes result from nonsense, missense, and frame-shifting mutations. These mutations, which are primarily caused by base substitutions, or one- or two-base deletions or insertions, are readily detectable by ESI-MS analysis.
  • ESI-MS can be used in the fields of disease gene detection, genotyping, tissue typing, and DNA forensics.
  • ESI-MS analysis of a set of base substitution polymorphisms can be use to uniquely identify an individual, and thus may be a useful forensic tool.
  • ESI-MS can also be used for tissue typing transplant or graft matching or for identifying pathogens, such as bacteria and viruses. This technique is also amenable to cancer dianostics by detecting the presence of a somatically mutated allele in either tissue biopsies or in blood.
  • ESI-MS analysis can be used as a technique to confirm the content of polymorphisms by detecting the expected alleles and then to rapidly screen for the presence of the alleles in genomes.
  • Genomic templates were prepared by phenol/chloroform extraction of blood or of biopsy material according to methods well known in the art, e.g. J. Sambrook et al. , Molecular Cloning: A Laboratory Manual (2d ed., 1989), hereby incorporated by reference. Oligonucleotides were either purchased from Genset or National Biosciences, or were synthesized according to methods well known in the art, e.g. S.A. Narang et al. , 68 Meth. Enzymol. 90 (1979); E.L. Brown et al. , 68 Meth. Enzymol. 109
  • Taq polymerase was purchased from either Perkin-Elmer or as "PCR SUPERMIX" from Gibco/BRL. PCR was carried out in either a Model 9600 or a Model 2400 Perkin-Elmer thermocycler according to methods well known in the art, e.g. U.S. Patent No. 4,683,195; U.S. Patent No. 4,683,202; U.S. Patent No. 4,800,159; U.S. Patent No. 4,965,188; PCR Technology: Principles and Applications for DNA Amplification (H. Erlich ed., Stockton Press,
  • PCR Protocols A guide to Methods and Applications (Innis et al . eds, Academic Press, San Diego, Calif., 1990), hereby incorporated by reference.
  • PCR amplification was generally optimized at 40 cycles as follows: annealing for 30 seconds at
  • the primers were SEQ ID NO:2 and SEQ ID NO:3.
  • PCR product purification was performed by either reverse phase HPLC, molecular weight cut-off spin filtration, or ethanol precipitation.
  • the PCR products were isolated by reverse phase HPLC, lyophilized to dryness, resuspended in deionized water, and then ethanol precipitated. The supernate was then removed from the precipitate by aspiration, and the precipitate was lyophilized once again. The dry precipitate was then dissolved in 80% methanol, 10 mM triethylamine (TEA) , and subjected to quadrupole mass analysis according to methods well known in the art.
  • TAA triethylamine
  • Reverse phase HPLC was performed on a Waters HPLC with buffer A: 100 mM TEA-bicarbonate, pH 7, and buffer B: 100 mM TEA-bicarbonate, pH 7, and 50% methanol. Gradient elution was with 0 to 100% buffer B in 60 minutes, and the column was a 4 mm x 300 mm PRP-3 from Hamilton. Molecular weight cut-off spin filters were MICROCON 3 and MICROCON 10 from Amicon. Ethanol precipitation was performed at a final concentration of 70% ethanol and 0.7 M ammonium acetate at -20°C for greater than 1 hour.
  • Samples for ESI-MS analysis were solvated in 80% methanol, 10 mM TEA, and then were injected into a Sciex QE mass spectrometer through a charged capillary. Ions were measured as a mass-to-charge ratio spectrum and then transformed into molecular weight spectra by the Fenn method, supra .
  • FIGS. 3 and 4 show, respectively, the m/z spectrum and the molecular weight transform spectrum of PCR products amplified according to this example. Four major peaks were observed (FIG. 4) , which are further characterized in Table 5.
  • peaks I and II correspond to the sense and antisense strands of the predicted amplification product.
  • peaks III and IV correspond to the 3 ' -mono-adenylation products of peaks I and II.
  • Taq polymerase is known to add such adenylate residues to amplification products in PCR.
  • Table 5 also shows that comparison of the masses measured from the four amplification products, peaks I-IV, to the expected masses for such products demonstrates a mass- determining accuracy to within 0.01% mass error.
  • Example 2 In this example, the procedure of Example 1 was followed except that genomic templates were from an individual homozygous at a polymorphic site and from another individual heterozygous at the polymorphic site.
  • SEQ ID N0:1 illustrates a portion of the sequence of the sense strand of one allele of the polymorphic site
  • SEQ ID NO:7 illustrates a corresponding portion of the sequence of the sense strand sequence of the other allele at the polymorphic site.
  • the two alleles differ only by a single base substitution.
  • the mass analysis resulted in one peak for each of the four expected strands (FIG. 5A) .
  • the mass analysis generated doublet peaks for each strand (FIG. 5B) .
  • the molecular weight observed for each peak in the doublet corresponds to the expected molecular weight from each allele.
  • the spectrum from the homozygote shows a peak for the expected adenylated antisense strand, but the spectrum from the heterozygote does not appear to have an expected doublet at this position.
  • the three other doublet peaks in the spectrum from the heterozygote each provide independent measurements of heterozygosity, thus the inherent redundancy of the technique enhances its robustness.
  • Example 3 In this example, oligonucleotides were synthesized to model all possible base substitution polymorphisms at the locus examined in Example 2. These four oligonucleotides were identical except for having a different base at the polymorphic site. The four oligonucleotides are SEQ ID N0:1, SEQ ID NO: 7,
  • Example 4 In this example, the procedure of Example 3 is followed except that SEQ ID NO:10 is substituted for SEQ ID NO:7.
  • the 23 dalton difference in molecular weight between dA and dU at the polymorphic locus results in the mixture of SEQ ID NO:8 and SEQ ID NO:10 being easily resolved.
  • ESI-MS genotyping in a four-member family for a C to T base substitution polymorphism was performed at a silent polymorphism locus in a candidate gene for Benign Neonatal Familial Convulsions (BNFC) .
  • the procedure was as in Example 1 except that the primers were SEQ ID NO:11 and SEQ ID NO:12.
  • the molecular weight spectra demonstrate detection of alleles, namely two alleles in the heterozygotic mother (A) and father (B) , and only one allele in the homozygotic daughters (C and D) .
  • ESI-MS analysis and assignment were performed without knowledge of which samples were homozygotic or heterozygotic. The assignment was confirmed by checking the sequence results from an automated sequencer that had previously been used to diagnose allele inheritance in the family. In comparison to the sequencing results, ESI-MS analysis demonstrates at least two advantages.
  • ESI-MS generates data on the composition of each strand, sense and antisense, in the analysis of one sample, whereas automated sequencing requires two separate sequencing reactions, i.e. with a forward primer and a reverse primer, to achieve data on each strand.
  • Example 6 In this example, ESI-MS technique was applied to disease inheritance detection. Analysis was performed on a family group with a defective allele for the Attenuated Polyposis Coli (APC) gene. The defective allele comprises a two-base deletion, which results in a 618 dalton difference between the PCR products of the alleles.
  • FIGS. 8A and 8D show the presence of peaks that are not present in the spectra FIGS. 8B and 8C, indicating the presence of the mutant allele.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

La présente invention concerne un procédé de détection d'un polymorphisme au niveau d'un site polymorphe appartenant au génome d'un individu. Ce procédé, qui consiste d'abord à amplifier une partie d'un échantillon d'ADN par réaction en chaîne de la polymérase de façon à produire un segment amplifié qui contienne le site polymorphe, consiste ensuite à faire le dessalage du segment amplifié, et consiste enfin à déterminer la masse du segment amplifié par spectrométrie de masse en phase ionisée par électro-pulvérisation. Pour confirmer la présence ou l'absence de polymorphisme, on compare à une masse de référence la masse du segment amplifié. L'invention concerne également des procédés de détection d'hétérozygosité et d'affections héréditaires par spectrométrie de masse en phase ionisée par électro-pulvérisation. La figure illustre la transformée du spectre de masse moléculaire obtenue à partir du spectre masse-sur-charge d'un oligonucléotide base 53.
PCT/US1997/008518 1996-06-10 1997-06-10 Identification precise et rapide de variantes de sequences d'adn par spectrometrie de masse en phase ionisee par electro-pulverisation Ceased WO1997047766A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP97930985A EP0954611A1 (fr) 1996-06-10 1997-06-10 Identification precise et rapide de variantes de sequences d'adn par spectrometrie de masse en phase ionisee par electro-pulverisation
JP10501607A JP2000512497A (ja) 1996-06-10 1997-06-10 エレクトロスプレー質量分析法による迅速で正確な変異体ｄｎａ配列の同定

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1970296P 1996-06-10 1996-06-10
US60/019,702 1996-06-10

Publications (1)

Publication Number Publication Date
WO1997047766A1 true WO1997047766A1 (fr) 1997-12-18

Family

ID=21794595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/008518 Ceased WO1997047766A1 (fr) 1996-06-10 1997-06-10 Identification precise et rapide de variantes de sequences d'adn par spectrometrie de masse en phase ionisee par electro-pulverisation

Country Status (4)

Country Link
EP (1) EP0954611A1 (fr)
JP (1) JP2000512497A (fr)
CA (1) CA2257866A1 (fr)
WO (1) WO1997047766A1 (fr)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2336206A (en) * 1998-01-27 1999-10-13 Bruker Daltonik Gmbh Method of enzymatic replication of genetic material in preparation for mass spectrometric analysis
GB2339279A (en) * 1998-05-29 2000-01-19 Bruker Daltonik Gmbh Mutation analysis using mass spectrometry
EP1176212A1 (fr) * 2000-07-24 2002-01-30 Centre National de Genotype Détermination des haplotypes par spectrométrie de masse
WO2004009849A1 (fr) * 2002-07-19 2004-01-29 Isis Pharmaceuticals, Inc. Procedes d'analyse par spectrometrie de masse au moyen d'une plate-forme d'echantillons microfluidique integree
EP1252336A4 (fr) * 2000-02-02 2005-02-09 Advion Biosciences Inc Detection de polymorphismes a nucleotide simple
EP2088209A1 (fr) * 1999-10-13 2009-08-12 Sequenom, Inc. Procédés de génération de bases de données et bases de données pour identifier des marqueurs génétiques polymorphes
US7956175B2 (en) 2003-09-11 2011-06-07 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US20110137022A1 (en) * 2008-08-20 2011-06-09 Dennis Paul Michaud Method for the analysis of oligonucleotides
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8017358B2 (en) 2001-03-02 2011-09-13 Ibis Biosciences, Inc. Method for rapid detection and identification of bioagents
US8026084B2 (en) 2005-07-21 2011-09-27 Ibis Biosciences, Inc. Methods for rapid identification and quantitation of nucleic acid variants
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8158936B2 (en) 2009-02-12 2012-04-17 Ibis Biosciences, Inc. Ionization probe assemblies
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
US8173957B2 (en) 2004-05-24 2012-05-08 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US8182992B2 (en) 2005-03-03 2012-05-22 Ibis Biosciences, Inc. Compositions for use in identification of adventitious viruses
US8187814B2 (en) 2004-02-18 2012-05-29 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8214154B2 (en) 2001-03-02 2012-07-03 Ibis Biosciences, Inc. Systems for rapid identification of pathogens in humans and animals
US8268565B2 (en) 2001-03-02 2012-09-18 Ibis Biosciences, Inc. Methods for identifying bioagents
US8298760B2 (en) 2001-06-26 2012-10-30 Ibis Bioscience, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
US8407010B2 (en) 2004-05-25 2013-03-26 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA
US8534447B2 (en) 2008-09-16 2013-09-17 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8550694B2 (en) 2008-09-16 2013-10-08 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
US8563250B2 (en) 2001-03-02 2013-10-22 Ibis Biosciences, Inc. Methods for identifying bioagents
US8822156B2 (en) 2002-12-06 2014-09-02 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US8871471B2 (en) 2007-02-23 2014-10-28 Ibis Biosciences, Inc. Methods for rapid forensic DNA analysis
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
US9149473B2 (en) 2006-09-14 2015-10-06 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
US9194877B2 (en) 2009-07-17 2015-11-24 Ibis Biosciences, Inc. Systems for bioagent indentification
US9249456B2 (en) 2004-03-26 2016-02-02 Agena Bioscience, Inc. Base specific cleavage of methylation-specific amplification products in combination with mass analysis
US9394565B2 (en) 2003-09-05 2016-07-19 Agena Bioscience, Inc. Allele-specific sequence variation analysis
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
US9873906B2 (en) 2004-07-14 2018-01-23 Ibis Biosciences, Inc. Methods for repairing degraded DNA
US9890408B2 (en) 2009-10-15 2018-02-13 Ibis Biosciences, Inc. Multiple displacement amplification
CN113881810A (zh) * 2021-11-02 2022-01-04 南方科技大学 一种新型冠状病毒病原微生物检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221518A (en) * 1984-12-14 1993-06-22 Mills Randell L DNA sequencing apparatus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221518A (en) * 1984-12-14 1993-06-22 Mills Randell L DNA sequencing apparatus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARCINOGENESIS, 1996, Vol. 17, No. 5, CHAUDHARY et al., "Characterization of an N6-Oxopropenyl-2'-Deoxyadenosine Adduct in Malondialdehyde-Modified DNA Using Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry", pages 1167-1170. *
EPILEPSIA, 1994, Vol. 35, Supplement 1, DELGADO-ESCUETA et al., "Progress in Mapping Epilepsy Genes", pages S29-S40. *
EUROPEAN JOURNAL OF CANCER, 1994, Vol. 30A, No. 11, DOBBIE et al., "Mutational Analysis of the First 14 Exons of the Adenomatous Polyposis Coli (APC) Gene", pages 1709-1713. *
PROCEEDINGS OF THE 41ST ASMA CONFERENCE ON MASS SPECTROMETRY AND ALLIED TOPICS, June 1993, HETTICH et al., "MALDI-FTMS for the Characterization of Ultraviolet and X-Ray Damage to Nucleic Acid Constituents", pages 250A and 250B. *
PROCEEDINGS OF THE 43RD ASMS CONFERENCE ON MASS SPECTROMETRY AND ALLIED TOPICS, 1995, ZHAO et al., "Capillary Isotachophoresis-Mass Spectrometric Determination of DNA Damage", page 592. *

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2336206A (en) * 1998-01-27 1999-10-13 Bruker Daltonik Gmbh Method of enzymatic replication of genetic material in preparation for mass spectrometric analysis
US6503710B2 (en) 1998-05-29 2003-01-07 Ivo Glynne Gut Mutation analysis using mass spectrometry
GB2339279A (en) * 1998-05-29 2000-01-19 Bruker Daltonik Gmbh Mutation analysis using mass spectrometry
GB2339279B (en) * 1998-05-29 2003-11-19 Bruker Daltonik Gmbh Mutation analysis using mass spectrometry
EP2088209A1 (fr) * 1999-10-13 2009-08-12 Sequenom, Inc. Procédés de génération de bases de données et bases de données pour identifier des marqueurs génétiques polymorphes
EP1252336A4 (fr) * 2000-02-02 2005-02-09 Advion Biosciences Inc Detection de polymorphismes a nucleotide simple
WO2002008462A1 (fr) * 2000-07-24 2002-01-31 Consortium National De Recherche En Genomique (Cnrg) Methode d'haplotypage par spectrometrie de masse
EP1176212A1 (fr) * 2000-07-24 2002-01-30 Centre National de Genotype Détermination des haplotypes par spectrométrie de masse
US8265878B2 (en) 2001-03-02 2012-09-11 Ibis Bioscience, Inc. Method for rapid detection and identification of bioagents
US8815513B2 (en) 2001-03-02 2014-08-26 Ibis Biosciences, Inc. Method for rapid detection and identification of bioagents in epidemiological and forensic investigations
US9752184B2 (en) 2001-03-02 2017-09-05 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US8268565B2 (en) 2001-03-02 2012-09-18 Ibis Biosciences, Inc. Methods for identifying bioagents
US9416424B2 (en) 2001-03-02 2016-08-16 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US8214154B2 (en) 2001-03-02 2012-07-03 Ibis Biosciences, Inc. Systems for rapid identification of pathogens in humans and animals
US8017358B2 (en) 2001-03-02 2011-09-13 Ibis Biosciences, Inc. Method for rapid detection and identification of bioagents
US8563250B2 (en) 2001-03-02 2013-10-22 Ibis Biosciences, Inc. Methods for identifying bioagents
US8802372B2 (en) 2001-03-02 2014-08-12 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US8921047B2 (en) 2001-06-26 2014-12-30 Ibis Biosciences, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US8380442B2 (en) 2001-06-26 2013-02-19 Ibis Bioscience, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
US8298760B2 (en) 2001-06-26 2012-10-30 Ibis Bioscience, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
WO2004009849A1 (fr) * 2002-07-19 2004-01-29 Isis Pharmaceuticals, Inc. Procedes d'analyse par spectrometrie de masse au moyen d'une plate-forme d'echantillons microfluidique integree
US8822156B2 (en) 2002-12-06 2014-09-02 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US9725771B2 (en) 2002-12-06 2017-08-08 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US8476415B2 (en) 2003-05-13 2013-07-02 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US9394565B2 (en) 2003-09-05 2016-07-19 Agena Bioscience, Inc. Allele-specific sequence variation analysis
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US7956175B2 (en) 2003-09-11 2011-06-07 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8013142B2 (en) 2003-09-11 2011-09-06 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
US9447462B2 (en) 2004-02-18 2016-09-20 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8187814B2 (en) 2004-02-18 2012-05-29 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US9249456B2 (en) 2004-03-26 2016-02-02 Agena Bioscience, Inc. Base specific cleavage of methylation-specific amplification products in combination with mass analysis
US8987660B2 (en) 2004-05-24 2015-03-24 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US9449802B2 (en) 2004-05-24 2016-09-20 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US8173957B2 (en) 2004-05-24 2012-05-08 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US8407010B2 (en) 2004-05-25 2013-03-26 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA
US9873906B2 (en) 2004-07-14 2018-01-23 Ibis Biosciences, Inc. Methods for repairing degraded DNA
US8182992B2 (en) 2005-03-03 2012-05-22 Ibis Biosciences, Inc. Compositions for use in identification of adventitious viruses
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
US8026084B2 (en) 2005-07-21 2011-09-27 Ibis Biosciences, Inc. Methods for rapid identification and quantitation of nucleic acid variants
US8551738B2 (en) 2005-07-21 2013-10-08 Ibis Biosciences, Inc. Systems and methods for rapid identification of nucleic acid variants
US9149473B2 (en) 2006-09-14 2015-10-06 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
US8871471B2 (en) 2007-02-23 2014-10-28 Ibis Biosciences, Inc. Methods for rapid forensic DNA analysis
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
US20110137022A1 (en) * 2008-08-20 2011-06-09 Dennis Paul Michaud Method for the analysis of oligonucleotides
US8609430B2 (en) 2008-09-16 2013-12-17 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8534447B2 (en) 2008-09-16 2013-09-17 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8252599B2 (en) 2008-09-16 2012-08-28 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US9027730B2 (en) 2008-09-16 2015-05-12 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US8550694B2 (en) 2008-09-16 2013-10-08 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
US9023655B2 (en) 2008-09-16 2015-05-05 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US9165740B2 (en) 2009-02-12 2015-10-20 Ibis Biosciences, Inc. Ionization probe assemblies
US8796617B2 (en) 2009-02-12 2014-08-05 Ibis Biosciences, Inc. Ionization probe assemblies
US8158936B2 (en) 2009-02-12 2012-04-17 Ibis Biosciences, Inc. Ionization probe assemblies
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
US9194877B2 (en) 2009-07-17 2015-11-24 Ibis Biosciences, Inc. Systems for bioagent indentification
US9890408B2 (en) 2009-10-15 2018-02-13 Ibis Biosciences, Inc. Multiple displacement amplification
CN113881810A (zh) * 2021-11-02 2022-01-04 南方科技大学 一种新型冠状病毒病原微生物检测方法

Also Published As

Publication number Publication date
CA2257866A1 (fr) 1997-12-18
JP2000512497A (ja) 2000-09-26
EP0954611A1 (fr) 1999-11-10

Similar Documents

Publication Publication Date Title
WO1997047766A1 (fr) Identification precise et rapide de variantes de sequences d'adn par spectrometrie de masse en phase ionisee par electro-pulverisation
US8133701B2 (en) Detection and quantification of biomolecules using mass spectrometry
US8383795B2 (en) Detection and quantification of biomolecules using mass spectrometry
Pusch et al. MALDI-TOF mass spectrometry-based SNP genotyping
Fu et al. Sequencing exons 5 to 8 of the p53 gene by MALDI-TOF mass spectrometry
JP5382802B2 (ja) 質量分析法を用いた生体分子の検出および定量
Braun et al. Detecting CFTR gene mutations by using primer oligo base extension and mass spectrometry
US6235476B1 (en) Process for detecting nucleic acids by mass determination
US7074597B2 (en) Multiplex genotyping using solid phase capturable dideoxynucleotides and mass spectrometry
EP1350851A1 (fr) Procede de detection de polymorphisme dans l'adn au moyen d'une spectroscopie de masse
EP1365031A1 (fr) Méthode pour la détection des mutations somatiques utilisant la spectrométrie de masse
Fei et al. Analysis of single nucleotide polymorphisms by primer extension and matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry
Little et al. Detection of RET proto-oncogene codon 634 mutations using mass spectrometry
WO1998012355A1 (fr) Procedes de preparation d'acides nucleiques pour des analyses de spectrometrie de masse
GB2339905A (en) Use of mass-specrometry for detection of mutations
US20050164193A1 (en) Method for the analysis of methylation patterns within nucleic acids by means of mass spectrometry
US20040058349A1 (en) Methods for identifying nucleotides at defined positions in target nucleic acids
US20020102556A1 (en) Genotyping by mass spectrometric analysis of short DNA fragments
Kim et al. Digital genotyping using molecular affinity and mass spectrometry
Srinivasan et al. Genotyping of Apolipoprotein E by matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry
WO2010071821A1 (fr) Test de diagnostic pour des mutations dans les codons 12-13 de k-ras humain
Il’ina et al. Mass spectrometry of nucleic acids in molecular medicine
Fei Single nucleotide polymorphism analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
Butler et al. High-Throughput STR Analysis by Time-of-Flight Mass Spectrometry
AU2009327432B2 (en) Diagnostic test for mutations in codons 12-13 of human K-RAS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2257866

Country of ref document: CA

Ref country code: CA

Ref document number: 2257866

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997930985

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997930985

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997930985

Country of ref document: EP